A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Z160 in Subjects With Postherpetic Neuralgia
Latest Information Update: 18 Dec 2013
At a glance
- Drugs Z 160 (Primary)
- Indications Postherpetic neuralgia
- Focus Therapeutic Use
- 11 Nov 2013 Status changed from active, no longer recruiting to completed.
- 11 Nov 2013 Primary endpoint 'Pain-intensity' has not been met.
- 11 Nov 2013 Results published in the Media Release.